Otsuka has finally lost its battle with the FDA to prevent generics of its antipsychotic Abilify from hitting the market. A federal judge issued a final ruling against the Japanese drugmaker, a little more than a month after regulators opened the door for copycat versions of the meds.
Merck's Keytruda gained some regulatory ground in Europe on Friday, nabbing a melanoma recommendation that Opdivo snagged last month. But Opdivo continued to charge ahead, too, winning a nod in lung cancer to help preserve its lead.
Gilead Sciences and AbbVie caught a break for their hepatitis C treatments when the FDA rescinded breakthrough designations earlier this year for potential competitors being developed by Merck and Bristol-Myers Squibb.
Pfizer and Bristol-Myers Squibb's new-age anticoagulant, Eliquis, has been ramping up after a slow start. But Johnson & Johnson, maker of market leader Xarelto, need not worry, thanks to that med's wide base of indications and hefty clinical trials program.
Johnson & Johnson and Bayer are wont to brag about their achievements with Xarelto, one of the new generation of anticoagulant meds. Rightfully so: Though second to that market by many months, the companies grabbed market share from their old standby rival warfarin and their head-to-head competition Pradaxa, too.
The curtain is up on the first act of the annual cancer drug lollapalooza at ASCO. The first round of abstracts spotlights a series of early winners--including Roche--and at least one big loser: Puma Biotechnology.
Federal authorities have rounded up nearly three dozen people indicted in a far-ranging scheme in which they allegedly sold $200 million worth of diverted drugs that included blockbusters like Bristol-Myers Squibb's antipsychotic Abilify, Gilead Sciences' HIV med Truvada and Novartis' cancer drug Gleevec.
Trained in his native Italy as a doctor, Giovanni Caforio speaks not only English and Italian, but also Spanish, French and Portuguese. As he steps into the CEO role today at Bristol-Myers Squibb, the question will be how well he speaks dollars and cents.
Just hours after Bristol-Myers Squibb beat Wall Street expectations with earnings that got a goose from antipsychotic Abilify, the FDA opened the floodgates to generics of the blockbuster.
Bristol-Myers Squibb was staring down the end of a barrel at the beginning of this year, bracing for a sales hit as its blockbuster antipsychotic Abilify nears patent expiration. But in an about-face, the drugmaker is celebrating first-quarter earnings that beat the Street's forecasts thanks to promising numbers for some of its newer meds.